Compounds and compositions as protein kinase inhibitors
US8202876B2 · kind B2 · utility
37Cited by
1References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 24, 2007 |
| Grant date | Jun 19, 2012 |
| Priority date | — |
| Expiry date | May 29, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.